These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 18039422)

  • 21. Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancer.
    Matos I; Elez E; Capdevila J; Tabernero J
    Expert Opin Emerg Drugs; 2016 Sep; 21(3):267-82. PubMed ID: 27578253
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A review of kinases implicated in pancreatic cancer.
    Giroux V; Dagorn JC; Iovanna JL
    Pancreatology; 2009; 9(6):738-54. PubMed ID: 20090395
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer.
    Carmi C; Mor M; Petronini PG; Alfieri RR
    Biochem Pharmacol; 2012 Dec; 84(11):1388-99. PubMed ID: 22885287
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epidermal growth factor receptor inhibitors in colorectal cancer treatment: what's new?
    Ponz-Sarvisé M; Rodríguez J; Viudez A; Chopitea A; Calvo A; García-Foncillas J; Gil-Bazo I
    World J Gastroenterol; 2007 Nov; 13(44):5877-87. PubMed ID: 17990353
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting receptor tyrosine kinases in gastric cancer.
    Morishita A; Gong J; Masaki T
    World J Gastroenterol; 2014 Apr; 20(16):4536-45. PubMed ID: 24782606
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tyrosine kinase inhibitors (TKIs) in human and pet tumours with special reference to breast cancer: a comparative review.
    Ranieri G; Pantaleo M; Piccinno M; Roncetti M; Mutinati M; Marech I; Patruno R; Rizzo A; Sciorsci RL
    Crit Rev Oncol Hematol; 2013 Nov; 88(2):293-308. PubMed ID: 23768779
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regorafenib: from bench to bedside in colorectal cancer.
    Shahda S; Saif MW
    Expert Rev Clin Pharmacol; 2013 May; 6(3):243-8. PubMed ID: 23656338
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systemic treatment of colorectal cancer in Serbia: what have we done and what can we offer in the new century?
    Popov I
    Acta Chir Iugosl; 2004; 51(2):117-21. PubMed ID: 15771302
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [New molecular-targeted agents for colorectal cancer - regorafenib and aflibercept].
    Kato S
    Gan To Kagaku Ryoho; 2013 Jan; 40(1):6-9. PubMed ID: 23306912
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systemic and targeted therapy for advanced colon cancer.
    Hegde SR; Sun W; Lynch JP
    Expert Rev Gastroenterol Hepatol; 2008 Feb; 2(1):135-49. PubMed ID: 19072376
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tropomyosin-related kinase B/brain derived-neurotrophic factor signaling pathway as a potential therapeutic target for colorectal cancer.
    Akil H; Perraud A; Jauberteau MO; Mathonnet M
    World J Gastroenterol; 2016 Jan; 22(2):490-500. PubMed ID: 26811602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tyrosine kinase inhibitors in the treatment of prostate cancer: taking the next step in clinical development.
    Ojemuyiwa MA; Madan RA; Dahut WL
    Expert Opin Emerg Drugs; 2014 Dec; 19(4):459-70. PubMed ID: 25345821
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New developments in the second-line treatment of metastatic colorectal cancer: potential place in therapy.
    Arnold D; Stein A
    Drugs; 2013 Jun; 73(9):883-91. PubMed ID: 23743737
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New target agents in the treatment of colorectal cancer patients.
    Tonini G; Schiavon G; Vincenzi B; Santini D
    Expert Opin Drug Discov; 2007 Jun; 2(6):861-71. PubMed ID: 23489003
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emerging tyrosine kinase inhibitors for head and neck cancer.
    Bossi P; Locati L; Licitra L
    Expert Opin Emerg Drugs; 2013 Dec; 18(4):445-59. PubMed ID: 24094093
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exploring alternative individualized treatment strategies in colorectal cancer.
    Wilson PM; Ladner RD; Lenz HJ
    Clin Colorectal Cancer; 2007 Dec; 7 Suppl 1():S28-36. PubMed ID: 18361804
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Integrating clinical pharmacology concepts in individualized therapy with tyrosine kinase inhibitors.
    Drenberg CD; Baker SD; Sparreboom A
    Clin Pharmacol Ther; 2013 Mar; 93(3):215-9. PubMed ID: 23419484
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Second-line therapy for advanced colorectal carcinoma.
    Starling N; Cunningham D
    Curr Oncol Rep; 2005 May; 7(3):173-80. PubMed ID: 15847707
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors.
    Terada T; Noda S; Inui K
    Pharmacol Ther; 2015 Aug; 152():125-34. PubMed ID: 25976912
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative safety and efficacy of tyrosine kinase inhibitors (TKIs) in the treatment setting of different types of leukemia, and different types of adenocarcinoma.
    Yazdi MH; Faramarzi MA; Nikfar S; Abdollahi M
    Biomed Pharmacother; 2017 Nov; 95():1556-1564. PubMed ID: 28950655
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.